In this May 4th interview, Dr. Barry Zingman helps viewers understand the significance of the preliminary results of the NIH/NIAID clinical trial of remdesivir for hospitalized COVID patients announced by Dr. Anthony Fauci, director of NIAID on April 29th. Dr. Zingman is leading the trial at Montefiore Health System | Albert Einstein College of Medicine, the first site in New York to join. Dr. Zingman explains that the results were announced early because it would have been unethical to withhold remdesivir from the patients in the placebo arm of the trial and the meaning of the term "breaking the blind."
He also discusses the strategy behind the second phase of the study, in which all enrolled patients will receive remdesivir, an antiviral drug and half will also receive an anti-inflammatory immune-modulating drug called baricitinib. The other half will receive remdesivir and a placebo. Dr. Zingman is clinical director of infectious diseases at Montefiore Health System (Moses Division) and professor of medicine at Albert Einstein College of Medicine. #remdesivir #coronavirusresearch #baricitinib #NIAID #NIH #covid19